Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma

This study is comparing two radiation schedules for elderly patients with glioblastoma (an aggressive brain cancer): a conventional schedule (daily treatments over several weeks) versus a shorter, more intense schedule (hypofractionated radiotherapy), both combined with the chemotherapy drug temozolomide. The aim is to find the approach that is most effective and easiest to tolerate in older patients. **You may be eligible if:** - You are 70 years or older - You have been newly diagnosed with glioblastoma (confirmed by pathology) - You have had surgery or biopsy within 4 weeks before joining the study - You are in reasonably good physical condition (Karnofsky score of 60 or above) - You have not previously received radiation to the brain or chemotherapy **You may NOT be eligible if:** - Your cancer has spread to the spine or spinal fluid - You have had prior brain radiation or chemotherapy - Your organ function is too poor to safely take temozolomide - You have another active cancer (with some minor exceptions) Talk to your doctor to see if this trial is right for you.